Skip to content
TrialMatch
Sign up
Recruiting

The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

Create a profile to match View the full record on ClinicalTrials.gov

About this study

This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.

Condition
Lung Cancer
Tested
Artificial Intelligence (AI) test, Research-use-only multimodal AI risk model
Sponsor
University of Illinois at Chicago

Who can join

Age
50 to 80 years
Sex
All sexes
Healthy volunteers
Accepted

Inclusion 10

  • Minimum age: 50 years
  • Maximum age: 80 years
  • Study condition: Lung Cancer
  • Participants must be 50-80 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
  • Participants must be eligible for LDCT screening as defined by the USPSTF
  • USPSTF-eligible patients at UI Health and Mile Square FQHC, including primary care and substance use disorder clinics.
  • Adults who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
  • Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. Consent provided by a legally authorized representative is not permitted in this protocol.
  • Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
  • Ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion 8

  • Adults who have more than 20 pack-years history but who have not smoked for 15 years or more prior to informed consent (i.e., quit smoking for 15 or more years).
  • Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
  • Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 5 years prior to the expected enrollment date, or diagnosed greater than 5 years prior to the expected enrollment date and never treated.
  • Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
  • Prior/Concurrent Concomitant Therapy (Medications/Treatments): Definitive treatment for invasive solid tumor or hematologic malignancy within the 5 years prior to the expected enrollment date. Adjuvant hormone therapy for cancer (e.g., for breast or prostate cancer) is not an exclusion criterion.
  • Individuals who will not be able to comply with the protocol procedures.
  • Individuals who are not currently registered patients at UIH
  • Current pregnancy (by self-report of pregnancy status)

Where

1 site, 1 recruiting

University of Illinois at Chicago

Chicago, Illinois, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.